We value the trust placed in us by our donors, supporters and the general public, and we feel the best way to continue to earn that trust is to make the association’s finances as transparent as possible. In fact, the American Heart Association has consistently met the high standards of the Better Business Bureau’s Wise Giving Alliance (WGA), the premier organization evaluating charitable organizations.

Financial support from corporations allows the American Heart Association’s programs and campaigns to more effectively advance our mission to reduce disability and death from cardiovascular disease and stroke.   All corporate relationships are required to comply with the association’s corporate relations policies and receive approval from two committees representing executive staff and national volunteers. 

Corporate funding received by the National Center from the pharmaceutical companies and device manufacturers listed represent approximately 2.9 percent of the association’s $697,244,815 in total revenue (2005-06 audited financial statements).  

The Pie Chart above illustrates that corporate donations to the National Center from pharmaceutical companies and device manufacturers represent approximately 2.9 percent of the association’s total revenue.

The Corporate Income to AHA National Center report shows pharmaceutical companies and device manufacturers that contributed more than $100,000 in fiscal year 2005-06. 

AHA Web Links

• 2006 Annual Report
• 2006 Audited Financial Statements
• 2006 Form 990 Schedule A and Statements
• Pharmaceutical Industry: AHA Advocacy Position, AHA Scientific Position

Archives

Corporate Income to AHA National Center (2004-2005)